Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations
Genes · 26.12.2023 · 15 (1) · 37
DOI: 10.3390/genes15010037 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 26.12.2023. Verfasst von Raafiah Izhar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. Hauptthemen laut MEDLINE: Fabry Disease, Lysosomal Storage Diseases. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fabry Disease (FD) is a rare lysosomal storage disorder caused by mutations in the GLA gene on the X chromosome, leading to a deficiency in α-galactosidase A (AGAL) enzyme activity. This leads to the accumulation of glycosphingolipids, primarily globotriaosylceramide (Gb3), in vital organs such as the kidneys, heart, and nervous system. While FD was initially considered predominantly affecting males, recent studies have uncovered that heterozygous Fabry women, carrying a single mutated GLA gene, can manifest a wide array of clinical symptoms, challenging the notion of asymptomatic carriers. The mechanisms underlying the diverse clinical manifestations in females remain not fully understood due to X-chromosome inactivation (XCI). XCI also known as “lyonization”, involves the random inactivation of one of the two X chromosomes. This process is considered a potential factor influencing phenotypic variation. This review delves into the complex landscape of FD in women, discussing its genetic basis, the available biomarkers, clinical manifestations, and the potential impact of XCI on disease severity. Additionally, it highlights the challenges faced by heterozygous Fabry women, both in terms of their disease burden and interactions with healthcare professionals. Current treatment options, including enzyme replacement therapy, are discussed, along with the need for healthcare providers to be well-informed about FD in women, ultimately contributing to improved patient care and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
- Department of Sperimental Medical and Surgical Sciences, Magna Graecia University, 88100 Catanzaro, Italy.
- Biogem S.c.a.r.l. Research Institute, 83031 Ariano Irpino, Italy.
- Nephrology and Dialysis Unit, Department of Translation Medical Sciences, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.
ORCID-Profile: Mariadelina Simeoni
Zitieren
APA
Izhar, R., Borriello, M., La Russa, A., Di Paola, R., De, A., Capasso, G., Ingrosso, D., Perna, A. F., & Simeoni, M. (2023). Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations. Genes, 15(1), 37. https://doi.org/10.3390/genes15010037
Vancouver
Izhar R, Borriello M, La Russa A, Di Paola R, De A, Capasso G, et al. Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations. Genes. 2023;15(1):37. doi:10.3390/genes15010037
BibTeX
@article{Izhar2023,
author = {Izhar, Raafiah and Borriello, Margherita and La Russa, Antonella and Di Paola, Rossella and De, Ananya and Capasso, Giovambattista and Ingrosso, Diego and Perna, Alessandra F and Simeoni, Mariadelina},
title = {Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations},
journal = {Genes},
year = {2023},
volume = {15},
number = {1},
pages = {37},
doi = {10.3390/genes15010037}
}
EUVIMED